Menu Investors Stock exchange announcements London (RNS) inside information London (RNS) inside information Date: 23.06.2021 11.00 - New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline Date: 10.03.2021 01.20 - Vir Biotechnology and GSK announce VIR-7831 reduces hospitalisation and risk of death in early treatment of adults with COVID-19 Date: 03.02.2021 12:00 - FY 2020 results announcement Date: 18.05.2020 07:00 - Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP Date: 23.12.2019 07:01 - ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV Date: 19.12.2018 07:00 - GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture Date: 03.12.2018 12:02 - GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company Date: 30.10.2018 14:30 - ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen Date: 14.06.2018 07:00 - ViiV Healthcare reports landmark phase III studies for dolutegravir and lamivudine, demonstrating the ability to control HIV with a two-drug regimen in treatment naïve patients Date: 27.03.2018 06:00 - GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business Date: 23.10.2017 07:00 - Shingrix approved in the US for prevention of shingles in adults aged 50 and over Date: 20.09.2016 07:00 - GSK appoints new CEO Date: 19.12.2016 22:01 - ViiV announce phase III results for 2-drug regimen RSS Other GSK websites Market website selector GSKPro for healthcare professionals GSK Study Register Quick links COVID-19 response Behind the science About us Products Careers Investors Media Research and development Responsibility Accessibility/legal Accessibility Terms of use Cookie policy Privacy notice Modern Slavery Act statement 2020 PDF - 191.4KB Sitemap Contact us Contact us Partnerships Report a possible side effect Business to business Supplier website Business to business This is our global website, intended for visitors seeking information on GSK’s worldwide business. Our market sites can be reached by visiting our market selector. © 2001-2021 GlaxoSmithKline plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies. GlaxoSmithKline plc. Registered in England and Wales No. 3888792. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. We use cookies GSK values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Others are optional: performance cookies show us how you use our website and features; functional cookies remember your preferences; and advertising cookies help us share relevant content.Cookie Policy Show detail ❮ OPT OUT ACCEPT ALL